Ask HopeStage to review this study with me
Study ID: NCT07225712. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT07225712
Safety study of SEP-363856 in schizophrenia
The registry lists this study as recruiting. Study locations are listed in Japan. Confirm recruitment at each site. It is testing SEP-363856 for schizophrenia.
SchizophreniaDrugOver 18 Years
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Japan · 1 site
- Jimbo Kokorono ClinicFukuokaSite status: Recruiting
Key information made simple
What is this study testing?
This study is testing whether SEP-363856 may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive SEP-363856, attend study visits with the research team. The registry lists locations in Japan.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: December 22, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- Over 18 Years
- Official registry ID
- NCT07225712
- Official title
- A Multicenter, Uncontrolled, Open-label Trial to Evaluate the Tolerability, Safety, and Efficacy of Long-term Administration of SEP-363856 in Patients With Schizophrenia
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT07225712. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving SEP-363856. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: Over 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Otsuka Pharmaceutical Co., Ltd., which appears to be a pharmaceutical company. Sponsor website: https://www.otsuka.co.jp/en/. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT07410507
Brenipatide in adults with Schizophrenia
The registry lists this study as recruiting. Study locations are listed in the United States, in Argentina, in Brazil, ... Confirm recruitment at each site. It is testing brenipatide for schizophrenia.
RecruitingNCT06585787
KarXT for Schizophrenia
The registry lists this study as recruiting. Study locations are listed in the United States, in France, in Belgium, ... Confirm recruitment at each site. It is testing KarXT for Schizophrenia.
RecruitingNCT06947941
Safety and Efficacy of KarXT + KarX-EC for Schizophrenia
The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in Canada, ... Confirm recruitment at each site. It is testing Safety and Efficacy of KarXT + KarX-EC for Schizophrenia.